ReviewJournal of cardiothoracic surgery2026
Technological advances and clinical application of left ventricular assist devices in the treatment of advanced heart failure.
Review in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left ventricular assist devices (LVADs) have become an important treatment for advanced heart failure, especially given the shortage of heart transplant donors. This article systematically reviews the technological evolution, perioperative assessment, pathophysiological changes, gender differences, functional recovery, and complication management of LVADs, focusing on the CH-VAD, a fully magnetically levitated centrifugal pump independently developed in China. Results show that LVAD technology has evolved from pulsatile flow devices to the third-generation magnetically levitated centrifugal pump, significantly improving blood compatibility and treatment safety. CH-VAD has demonstrated good efficacy and safety in clinical applications, with a 6-month and 1-year survival rate of 91.6%, a low rate of drive-line infection (11.0%), and unique advantages in complex anatomical cases. LVADs can effectively improve patients' cardiac function, quality of life, and exercise tolerance, promoting cardiac remodeling and skeletal muscle recovery, but hemodynamic regulation during exercise remains limited. The risk of complications (stroke, infection) remains higher in female patients than in male patients. The prediction and management of right heart failure remains a key challenge affecting prognosis. In the future, it is necessary to combine biomarker-guided patient screening, gender-specific risk management, and the technological iteration of domestically produced equipment to promote the individualization and precision of LVAD treatment.
Indexed as
Identifiers
42477813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.